Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2010, Article ID 720305, 8 pages
http://dx.doi.org/10.1155/2010/720305
Review Article

Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension

1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi,Shinjuku-ku, Tokyo 160-8582, Japan
2Department of Cardiology, Kyorin University Graduate School of Medicine, Mitaka, Tokyo 181-8611, Japan

Received 13 May 2010; Accepted 6 July 2010

Academic Editor: Oliver Distler

Copyright © 2010 Yoshiaki Furuya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Condliffe, D. G. Kiely, A. J. Peacock et al., “Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 2, pp. 151–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. V. D. Steen and T. A. Medsger, “Changes in causes of death in systemic sclerosis, 1972–2002,” Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 940–944, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. K. M. Chin, N. H. S. Kim, and L. J. Rubin, “The right ventricle in pulmonary hypertension,” Coronary Artery Disease, vol. 16, no. 1, pp. 13–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. E. T. Koh, P. Lee, D. D. Gladman, and M. Abu-Shakra, “Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients,” British Journal of Rheumatology, vol. 35, no. 10, pp. 989–993, 1996. View at Google Scholar · View at Scopus
  5. M. Humbert, O. Sitbon, and G. Simonneau, “Treatment of pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 351, no. 14, pp. 1425–1473, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Budhiraja, R. M. Tuder, and P. M. Hassoun, “Endothelial dysfunction in pulmonary hypertension,” Circulation, vol. 109, no. 2, pp. 159–165, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. S. M. Kawut, D. B. Taichman, C. L. Archer-Chicko, H. I. Palevsky, and S. E. Kimmel, “Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis,” Chest, vol. 123, no. 2, pp. 344–350, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. M. R. Fisher, S. C. Mathai, H. C. Champion et al., “Clinical differences between idiopathic and scleroderma-related pulmonary hypertension,” Arthritis & Rheumatism, vol. 54, no. 9, pp. 3043–3050, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Hachulla, P. Carpentier, V. Gressin et al., “Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study,” Rheumatology, vol. 48, no. 3, pp. 304–308, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Hachulla, D. Launay, A. Yaici et al., “Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome,” Rheumatology, vol. 49, no. 5, pp. 940–944, 2010. View at Google Scholar
  11. A. Dham and B. A. Peterson, “Castleman disease,” Current Opinion in Hematology, vol. 14, no. 4, pp. 354–359, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Yoshizaki, T. Matsuda, N. Nishimoto et al., “Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease,” Blood, vol. 74, no. 4, pp. 1360–1367, 1989. View at Google Scholar · View at Scopus
  13. A. Katsume, H. Saito, Y. Yamada et al., “Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice,” Cytokine, vol. 20, no. 6, pp. 304–311, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Nishimoto, Y. Kanakura, K. Aozasa et al., “Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease,” Blood, vol. 106, no. 8, pp. 2627–2632, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Soulier, L. Grollet, E. Oksenhendler et al., “Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease,” Blood, vol. 86, no. 4, pp. 1276–1280, 1995. View at Google Scholar · View at Scopus
  16. A. Gessain, A. Sudaka, J. Briere et al., “Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease: is there any relevant association in non-human immunodeficiency virus-infected patients?” Blood, vol. 87, no. 1, pp. 414–416, 1996. View at Google Scholar · View at Scopus
  17. T. M. Bull, C. D. Cool, A. E. Serls et al., “Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8,” European Respiratory Journal, vol. 22, no. 3, pp. 403–407, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Montani, L. Achouh, A. G. Marcelin et al., “Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease,” European Respiratory Journal, vol. 26, no. 5, pp. 969–972, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Taniguchi, C. Shimazaki, Y. Fujimoto et al., “Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease,” International Journal of Hematology, vol. 90, no. 1, pp. 99–102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. A. Radkov, P. Kellam, and C. Boshoff, “The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells,” Nature Medicine, vol. 6, no. 10, pp. 1121–1127, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. E. H.-Y. Cheng, J. Nicholas, D. S. Bellows et al., “A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 2, pp. 690–694, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. C. D. Cool, P. R. Rai, M. E. Yeager et al., “Expression of human herpesvirus 8 in primary pulmonary hypertension,” The New England Journal of Medicine, vol. 349, no. 12, pp. 1113–1122, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Humbert, G. Monti, F. Brenot et al., “Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension,” American Journal of Respiratory and Critical Care Medicine, vol. 151, no. 5, pp. 1628–1631, 1995. View at Google Scholar · View at Scopus
  24. N. Selimovic, C.-H. Bergh, B. Andersson, E. Sakiniene, H. Carlsten, and B. Rundqvist, “Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension,” European Respiratory Journal, vol. 34, no. 3, pp. 662–668, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. R. M. Tuder, M. Chacon, L. Alger et al., “Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis,” The Journal of Pathology, vol. 195, no. 3, pp. 367–374, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Yoshio, J.-I. Masuyama, N. Kohda et al., “Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE,” The Journal of Rheumatology, vol. 24, no. 3, pp. 489–495, 1997. View at Google Scholar · View at Scopus
  27. T. Nishimaki, S. Aotsuka, H. Kondo et al., “Immunological analysis of pulmonary hypertension in connective tissue diseases,” The Journal of Rheumatology, vol. 26, no. 11, pp. 2357–2362, 1999. View at Google Scholar · View at Scopus
  28. P. Gourh, F. C. Arnett, S. Assassi et al., “Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations,” Arthritis Research & Therapy, vol. 11, no. 5, p. R147, 2009. View at Google Scholar
  29. P. Lesprit, B. Godeau, F.-J. Authier et al., “Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 3, pp. 907–911, 1998. View at Google Scholar · View at Scopus
  30. L. Savale, L. Tu, D. Rideau et al., “Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice,” Respiratory Research, vol. 10, p. 6, 2009. View at Google Scholar · View at Scopus
  31. A. Bhargava, A. Kumar, N. Yuan, M. H. Gewitz, and R. Mathew, “Monocrotaline induces interleukin-6 mRNA expression in rat lungs,” Heart Disease, vol. 1, no. 3, pp. 126–132, 1999. View at Google Scholar · View at Scopus
  32. M. Miyata, M. Ito, T. Sasajima, H. Ohira, and R. Kasukawa, “Effect of a serotonin receptor antagonist on interleukin-6-induced pulmonary hypertension in rats,” Chest, vol. 119, no. 2, pp. 554–561, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Kishimoto, “IL-6: from its discovery to clinical applications,” International Immunology, vol. 22, no. 5, pp. 347–352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. G. G. Pietra, F. Capron, S. Stewart et al., “Pathologic assessment of vasculopathies in pulmonary hypertension,” Journal of the American College of Cardiology, vol. 43, no. 12, pp. 25S–32S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. R. M. Tuder, B. Groves, D. B. Badesch, and N. F. Voelkel, “Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension,” American Journal of Pathology, vol. 144, no. 2, pp. 275–285, 1994. View at Google Scholar · View at Scopus
  36. M. K. Steiner, O. L. Syrkina, N. Kolliputi, E. J. Mark, C. A. Hales, and A. B. Waxman, “Interleukin-6 overexpression induces pulmonary hypertension,” Circulation Research, vol. 104, no. 2, pp. 236–244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. S. Yao, W. Zhai, Y. Fan et al., “Interleukin-6 upregulates expression of KDR and stimulates proliferation of human cerebrovascular smooth muscle cells,” Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 3, pp. 510–520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. C. D. Cool, D. Kennedy, N. F. Voelkel, and R. M. Tuder, “Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection,” Human Pathology, vol. 28, no. 4, pp. 434–442, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Rabinovitch, “Molecular pathogenesis of pulmonary arterial hypertension,” The Journal of Clinical Investigation, vol. 118, no. 7, pp. 2372–2379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Atkinson, S. Stewart, P. D. Upton et al., “Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor,” Circulation, vol. 105, no. 14, pp. 1672–1678, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Brock, M. Trenkmann, R. E. Gay et al., “Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway,” Circulation Research, vol. 104, no. 10, pp. 1184–1191, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. B. P. Lewis, C. B. Burge, and D. P. Bartel, “Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets,” Cell, vol. 120, no. 1, pp. 15–20, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Tagawa, K. Karube, S. Tsuzuki, K. Ohshima, and M. Seto, “Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development,” Cancer Science, vol. 98, no. 9, pp. 1482–1490, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. M. E. Yeager, G. R. Halley, H. A. Golpon, N. F. Voelkel, and R. M. Tuder, “Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension,” Circulation Research, vol. 88, no. 1, pp. E2–E11, 2001. View at Google Scholar · View at Scopus
  45. A. Papapetropoulos, D. Fulton, K. Mahboubi et al., “Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway,” The Journal of Biological Chemistry, vol. 275, no. 13, pp. 9102–9105, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Kugathasan, J. B. Ray, Y. Deng, E. Rezaei, D. J. Dumont, and D. J. Stewart, “The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice,” The Journal of Experimental Medicine, vol. 206, no. 10, pp. 2221–2234, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. F. A. Masri, W. Xu, S. A. A. Comhair et al., “Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension,” American Journal of Physiology, vol. 293, no. 3, pp. L548–L554, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Imaizumi, H. Yoshida, and K. Satoh, “Regulation of CX3CL1/fractalkine expression in endothelial cells,” Journal of atherosclerosis and thrombosis, vol. 11, no. 1, pp. 15–21, 2004. View at Google Scholar · View at Scopus
  49. M. Hagen, K. Fagan, W. Steudel et al., “Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle,” American Journal of Physiology, vol. 292, no. 6, pp. L1473–L1479, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. S. M. Golembeski, J. West, Y. Tada, and K. A. Fagan, “Interleukin-6 mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice,” Chest, vol. 128, supplement 6, pp. 572S–573S, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Savale, M. Izikki, and L. Tu, “Attenuated hypoxic pulmonary hypertension in mice lacking the interleukin-6 gene,” American Journal of Respiratory and Critical Care Medicine, vol. 175, p. A42, 2007. View at Google Scholar
  52. J. H. Newman, R. C. Trembath, J. A. Morse et al., “Genetic basis of pulmonary arterial hypertension: current understanding and future directions,” Journal of the American College of Cardiology, vol. 43, no. 12, pp. 33S–39S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Song, J. E. Jones, H. Beppu, J. F. Keaney Jr., J. Loscalzo, and Y.-Y. Zhang, “Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice,” Circulation, vol. 112, no. 4, pp. 553–562, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Sato, M. Hasegawa, and K. Takehara, “Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis,” Journal of Dermatological Science, vol. 27, no. 2, pp. 140–146, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Schmidt, L. Martinez-Gamboa, S. Meier et al., “Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients,” Arthritis Research & Therapy, vol. 11, no. 4, p. R111, 2009. View at Google Scholar
  56. C. A. Feghali, K. L. Bost, D. W. Boulware, and L. S. Levy, “Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma,” The Journal of Rheumatology, vol. 19, no. 8, pp. 1207–1211, 1992. View at Google Scholar · View at Scopus
  57. B. Crestani, N. Seta, M. De Bandt et al., “Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement,” American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 5, pp. 1260–1265, 1994. View at Google Scholar · View at Scopus
  58. R. T. Schermuly, E. Dony, H. A. Ghofrani et al., “Reversal of experimental pulmonary hypertension by PDGF inhibition,” The Journal of Clinical Investigation, vol. 115, no. 10, pp. 2811–2821, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. H. A. Ghofrani, W. Seeger, and F. Grimminger, “Imatinib for the treatment of pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 353, no. 13, pp. 1412–1413, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. K. C. Patterson, A. Weissmann, T. Ahmadi, and H. W. Farber, “Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension,” Annals of Internal Medicine, vol. 145, no. 2, pp. 152–153, 2006. View at Google Scholar · View at Scopus
  61. R. Souza, O. Sitbon, F. Parent, G. Simonneau, and M. Humbert, “Long term imatinib treatment in pulmonary arterial hypertension,” Thorax, vol. 61, no. 8, p. 736, 2006. View at Publisher · View at Google Scholar · View at Scopus